Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;45(3):1307-1309.
doi: 10.1007/s10072-023-07122-y. Epub 2023 Oct 24.

Efgartigimod improves triple-negative myasthenia gravis

Rita Frangiamore  1 , Elena Rinaldi  1 , Fiammetta Vanoli  1   2 , Francesca Andreetta  1 , Renato Mantegazza  1 , Carlo Antozzi  3   4
Affiliations

Efgartigimod improves triple-negative myasthenia gravis

Rita Frangiamore et al. Neurol Sci. 2024 Mar.
No abstract available

PubMed Disclaimer

References

    1. Nair SS, Jacob S (2023) Novel immunotherapies for myasthenia gravis. Immunotargets Ther 12:25–45 - DOI - PubMed - PMC
    1. Zuercher AW, Spring R, Morelli BA, Rowe T, Kasermann F (2019) Next-generation Fc receptor-targeting biologics for autoimmune diseases. Autoimmun Rev 18:102366 - DOI - PubMed
    1. Howard JF, Bril V, Burns TM et al (2019) Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology 92:e2661-2673 - DOI - PubMed - PMC
    1. Howard JF Jr, Bril V et al (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalized myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20:526–536 - DOI - PubMed
    1. Heo YA (2022) Efgartigimod: first approval. Drugs 82:341–348 - DOI - PubMed - PMC

LinkOut - more resources